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oxetanoribonucleosides 
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a
Bioorganic Laboratory, Department of Chemistry, University of Delhi, Delhi-110 007, India 
b
Department of Chemistry, University of Southampton, Highfield, Southampton, SO17 1BJ, UK 
 
Abstract 
The lipase, Novozyme
®
-435 exclusively deacetylates the 5-O-acetyl over 4-C-
acetyloxymethyl group of almost identical reactivity in 5-O-acetyl-4-C-acetyloxymethyl-3-
azido-3-deoxy-1,2-O-isopropylidene-α-D-ribofuranose that led to the development of first and 
efficient synthesis of 3'-azido- / 3'-amino- C-4'-spiro-oxetanoribonucleosides T, U, C and A in  
20 to 24 % overall yields. The X-ray study on the compound obtained by tosylation of lipase-
mediated monodeacetylated product unambiguously confirmed the point of diastereoselective 
monodeacetylation on diacetoxy-azido-ribofuranose derivative. The capability of 
Novozyme
®
-435 for selective deacylation of 5-O-acetyl group in 5-O-acetyl-4-C-
acetyloxymethyl-3-O-benzyl-1,2-O-isopropylidene-α-D-ribofuranose recently discovered by us 
has been successfully used for the synthesis of C-4'-spiro-oxetanoribonucleosides A and C in 
good yields. These results clearly indicate that the broader substrate specificity and highly 
selective capability of Novozyme
®
-435 for carrying out acetylation/deacetylation reactions 
can be utilised for the development of environment friendly selective methodologies in 
organic synthesis.   
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1. Introduction 
 The first naturally occurring spironucleoside (+)-hydantocidin (1) was isolated from 
the bacterial culture broth of Streptomyces hygroscopicus SANK 63584
1 
and is known for its 
herbicidal and plant growth regulatory activities without exhibiting any mammalian toxicity.
2 
Recently, it has been reported that the presence of a spiro-carbon in  nucleosides restricts the 
conformational flipping of the furanose ring and thus enhances their biological activity.
3,4 
This has led to the synthesis of different spironucleosides, such as C-1'-spiro-,
5
 C-2'-spiro-,
4
 
C-3'-spiro-
6
 and C-4'-spiro- nucleosides
7,8
 2 - 6 (Figure 1).
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The C-4'-spironucleosides imparts some distinct advantages including; (a) restriction in 
conformational flexibility to sugar moiety that may allow the molecule to attain the optimal 
puckering needed for drug action; (b) inhibition of the free radical-induced degradation of 
nucleos(t)ides by C-4'-proton abstraction and (c) serves as conformationally fixed models for 
elucidation of the glycosidic torsion angle in nucleosides.
9,10 
Recently we have disclosed the first 
chemoenzymatic synthesis of C-4'-spiro-oxetanoribonucleosides U and T (6, Figure 1) by 
utilizing the lipase-mediated diastereoselective deacetylation of one of the two diastereotopic 
acetyl groups of 4-C-acetoxymethyl-5-O-acetyl-3-O-benzyl-1,2-O-isopropylidene-α-D-
ribofuranose.
8
 Herein, we report the first synthesis of 3'-azido- / 3'-amino- C-4'-spiro-
oxetanoribonucleosides T, U, C and A starting from lipase-mediated exclusive 
diastereoselective deacetylation of the required acetoxy group from 5-O-acetyl-4-C-
acetyloxymethyl-3-azido-3-deoxy-1,2-O-isopropylidene-α-D-ribofuranose along with the 
synthesis of  C-4'-spiro-oxetanoribonucleosides A and C following our earlier developed 
chemo-enzymatic methodology in excellent to good yields.  
2. Results and Discussion 
The key starting sugar derivative, i.e. diacetoxy-azido-ribofuranose 8
 
was synthesized in 
90 % yield by per-acetylation of the corresponding dihydroxy compound 3-azido-3-deoxy-4-
C-hydroxymethyl-1,2-O-isopropylidene-α-D-ribofuranose (7) which in turn was synthesized 
from D-glucose following literature procedure in 44 % overall yield.
11,12
 For the synthesis of 
targeted azido-spironucleosides our aim was to find out a suitable lipase for diastereoselective 
deacetylation of 5-O-acetyl over 4-C-acetyloxymethyl group of diacetoxy-azido-ribofuranose 
8. On screening of different lipases,
13
 viz. Candida antarctica lipase-B immobilized on 
polyacrylate (Lewatit), commonly known as Novozyme
®
-435, Thermomyces lanuginosus 
lipase immobilized on silica (Lipozyme
®
 TL IM), Candida rugosa lipase (CRL) and porcine 
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pancreatic lipase (PPL), the lipase Novozyme
®
-435 (35 % w/w of the substrate) in THF at 50 
o
C was found to be selective for efficient deacetylation of C-5 acetoxy over the other acetoxy 
group in compound 8 (Scheme 1). Thus, Novozyme
®
-435 mediated deacetylation of 
diacetoxy-azido-ribofuranose 8 in THF containing a small amount of n-butanol in an 
incubator shaker at 200 rpm and at 50 
o
C led to the formation of 4-C-acetoxymethyl-3-azido-
3-deoxy-1,2-O-isopropylidene-α-D-ribofuranose (9) in 95 % yield (Scheme 1). The structure 
of monodeacetylated compound 9 was unambiguously established on the basis of its 
1
H- & 
13
C- NMR spectra, IR spectra and HRMS data analysis, which was further confirmed by X-
ray diffraction analysis of single crystal of its tosyl derivative, 4-C-acetoxymethyl-3-azido-3-
deoxy-5-O-(p-toluenesulphonyl)-1,2-O-isopropylidene-α-D-ribofuranose (10) obtained by 
tosylation of compound 9 with TsCl-pyridine in 91 % yield (Scheme 1, Figure 2). 
 
Recently, it has been revealed that the incubation of 3-azido-3-deoxy-4-C-
hydroxymethyl-1,2-O-isopropylidene-α-D-ribofuranose (7) with Novozyme®-435 in toluene 
in the presence of vinyl acetate leads to the exclusive formation of 5-O-acetyl-3-azido-3-
deoxy-4-C-hydroxymethyl-1,2-O-isopropylidene-α-D-ribofuranose by selective transfer of 
the acetyl group from acetylating agent to C-5 OH group of the dihydroxy sugar derivative. 
This enzymatic methodology of selective acetylation of dihydroxy sugar derivative 7 has 
been used for environment friendly lipase-mediated synthesis of azido-LNA monomers.
11
 
This indicates that during Novozyme
®
-435-mediated acetylation / deacetylation reaction the 
substrate is bound to the catalytic site of the lipase in such a way that only C-5 OH/OAc is 
exposed for the reaction.
8,11,14
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  Acetolysis of tosylated compound 10 with acetic acid-acetic anhydride-sulphuric acid 
(100:10:0.1) afforded the triacetoxy sugar derivative 11a-11b in 94 % yield, which on 
coupling with nucleobases thymine, uracil, cytosine and 6-N-benzoyladenine under 
Vorbrüggen coupling condition
15
 in the presence of N,O-bis(trimethylsilyl)acetamide and 
trimethylsilyltrifluoromethane sulfonate in acetonitrile or in 1,2-dichloroethane (only for 6-N-
benzoyladenine) resulted in the formation of nucleoside 12a-d in 81-85 % yields. Treatment 
of diacetylated nucleosides 12a-d with 2M NaOH solution in water:dioxane resulted in the 
deacetylation followed by ring-closure through SN
2
 reaction between C-4'-hydroxymethyl and 
C-5'-O-tosyl group to afford 3'-azido-3'-deoxy-C-4'-spiro-oxetanoribonucleosides T, U, A 
and C 13a-d in 80-93 % yields. Further, it has been demonstrated as a model case that the 
azido group of 3'-azido-3'-deoxy-C-4'-spiro-oxetanoribothymidine (13a) can be reduced with 
Pd-C under hydrogen atmosphere in ethyl acetate to afford the corresponding amino-
nucleoside, i.e. 3'-amino-3'-deoxy-C-4'-spiro-oxetanoribothymidine (14) in 99 % yield 
(Scheme 2).    
 
     
.          Further in continuation of our recent report, two C-4'-spiro-oxetanoribonucleosides A 
and C were synthesized in good yields utilizing the capability of Novozyme
®
-435 for 
diastereoselective deacetylation of 5-O-acetyl group in 5-O-acetyl-4-C-acetyloxymethyl-3-O-
benzyl-1,2-O-isopropylidene-α-D-ribofuranose .8 Thus the monotosylated triacetoxy glycosyl 
donor 16 was prepared from enzymatically monodeacetylated sugar derivative 15 according 
to the literature procedure in 92 % overall yields (Scheme 3). The coupling of the glycosyl 
donor 16 with nucleobases 6-N-benzoyladenine and cytosine under Vorbrüggen coupling 
condition
15
 in the presence of N,O-bis(trimethylsilyl)acetamide and 
trimethylsilyltrifluoromethane sulfonate in acetonitrile or in 1,2-dichloroethane (for 6-N-
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benzoyladenine) resulted in the formation of 4'-C-acetoxymethyl-2'-O-acetyl-3'-O-benzyl-5'-
O-p-toluenesulphonyl- 6-N-benzoyladenosine (17a) and cytidine (17b) in 74 and 81 % yields, 
respectively (Scheme 3). The treatment of tosylated nucleosides 17a and 17b with aq. NaOH-
dioxane-NH4OH and aq. NaOH-dioxane led to the hydrolysis of acetoxy group and concomitant 
cyclization via SN
2
 reaction between C-4'-hydroxymethyl and C-5'-O-tosyl group to afford 3'-
O-benzyl- C-4'-spiro-oxetanoriboadenosine (18a) and 3'-O-benzyl- C-4'-spiro-
oxetanoribocytidine (18b) in 68 and 71 % yields, respectively. The deprotection of 3′-O-
benzyl group in nucleosides 18a with Pd(OH)2-C and HCOONH4 in ethanol afforded C-4'-spiro-
oxetanoriboadenosine 19 in 73 % yields (Scheme 3). However, several attempts to affect 
debenzylation on nucleoside 18b using reagents, such as Pd-C in presence of H2, 20 % Pd(OH)2-C 
in presence of HCOONH4, 20 % Pd(OH)2-C in presence of HCOOH, 1M BCl3 in 
dichloromethane, etc. led to the formation of inseparable mixture of compounds. 
 
The structures of all synthesized compounds 7, 8, 9, 10, 11a-11b, 12a-d, 13a-d, 14, 15, 
16a-16b, 17a & 17b, 18a & 18b and 19 were unambiguously established on the basis of their 
spectral data (
1
H- & 
13
C- NMR spectra, IR spectra and HRMS) analysis. The structure of 
known compounds 7, 15 and 16a-16b were further confirmed on the basis of comparison of 
their physical and spectral data with those reported in the literature.
8,11,12
  Further, single 
crystal X-ray diffraction analysis has been performed on 3′-O-benzyl-C-4'-spiro-
oxetanoribouridine (20) recently synthesized and reported by us.
8
 The X-ray data analysis has 
revealed important structural features of 3'-hydroxy- / 3'-azido- C-4'-spiro-
oxetanoribonucleosides, which is in consonance with the literature report.
3,4
 The study clearly 
indicates that the presence of a spiro carbon restricts the conformational flipping of the 
furanose ring and the sugar puckering in C-4'-spiro-oxetanoribonucleosides attain N-type 
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conformation (Figure 3). The detailed crystallographic data of compounds 10 and 20 has been 
deposited in the Cambridge Crystallographic Data Centre with CCDC nos. 951084 and 
1032754, respectively. 
 
 
 
 
3. Conclusion 
In summary, Novozyme
®
-435 catalyzed deacetylation methodology has been 
optimised for exclusive diastereoselective monodeacetylation of C-5 acetoxy group in 5-O-
acetyl-4-C-acetyloxymethyl-3-azido-3'-deoxy-1,2-O-isopropylidene-α-D-ribofuranose. The 
developed methodology has been successfully used for the efficient synthesis of 3'-azido- / 3'-
amino- C-4'-spiro-oxetanoribonucleosides T, U, C and A. In continuation, recently developed 
enzymatic methodology for diastereoselective  decaetylation of one of the two acetoxy group 
present in 5-O-acetyl-4-C-acetyloxymethyl-3-O-benzyl-1,2-O-isopropylidene-α-D-ribofuranose 
has been used for the synthesis of C-4'-spiro-oxetanoribonucleosides A and C. The X-ray 
crystal data analysis on 3′-O-benzyl-C-4'-spiro-oxetanoribouridine revealed important structural 
features of 3'-hydroxy- / 3'-azido- C-4'-spiro-oxetanoribonucleosides,  i.e. presence of spiro 
carbon restricts the conformational flipping of furanose ring and the sugar puckering in C-4'-
spiro-oxetanoribonucleosides attains N-type conformation which is in consonance with the 
literature report.
 
In addition,
 
the broader substrate specificity and highly selective nature of 
Novozyme
®
-435 can be utilised for the development of environment friendly selective 
methodologies in organic synthesis. 
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4. Experimental Section 
Melting points were determined on Buchi M-560 instrument and are uncorrected. The 
IR spectra were recorded on a Perkin-Elmer model 2000 FT-IR spectrometer by making KBr 
disc for solid samples and thin film for oils. The 
1
H- and 
13
C- NMR spectras were recorded at 
Jeol alpha-400 spectrometer at 400 and 100.6 MHz, respectively using TMS as internal 
standard. The chemical shift values are on  scale and the coupling constants (J) are in Hz. 
The mass spectra analyses were done on a microTOF-Q instrument from Bruker Daltonics, 
Bremen and 6520 Q-TOF instrument from Agilent Technologies. The optical rotations were 
measured on Rudolph Autopol II automatic polarimeter using light of 546 nm wavelength. 
Analytical TLCs were performed on precoated Merck silica-gel 60F254 plates; the spots were 
detected either under UV light or by charring with 4 % alcoholic H2SO4. Silica gel (100-200 
mesh) was used for column chromatography. The single crystal X-ray diffraction data was 
collected on an Oxford Diffraction X’Calibur single crystal X-ray instrument having CCD 
camera [Cu Kα radiation (λ = 1.54184)] at USIC, University of Delhi, Delhi.  
4-C-Acetoxymethyl-5-O-acetyl-3-azido-3-deoxy-1,2-O-isopropylidene-α-D-ribofuranose 
(8). To a solution of compound 7 (1.0 g, 4.08 mmol) in THF (10 mL) were added DMAP (97 
mg, 0.79 mmol) and Ac2O (1.15 mL, 12.17 mmol) and the reaction mixture was stirred at 
room temperature for 4 h. On completion, the mixture was diluted with cold water (25 mL) 
and extracted with ethyl acetate (3 x 100 mL). The combined organic layer was washed with 
cold water (2 x 50 mL), dried over sodium sulphate and concentrated under reduced pressure. 
The residue thus obtained was purified by column chromatography using ethyl acetate in 
petroleum ether as gradient solvent system to afford compound 8 as colourless oil (1.21 g, 
90 % yield). Rf  = 0.6 (40 % ethyl acetate in petroleum ether); [α]D
25
 =
  
+ 48.78 (c = 0.1, 
MeOH); IR (thin film) max: 2115, 1744, 1675, 1458, 1385, 1229, 1167, 1119, 1046 and 873 
Page 8 of 27
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cm
-1
; 
1
H NMR (CDCl3, 400 MHz):  1.35 (3H, s), 1.64 (3H, s), 2.11 (6H, s), 4.10 (1H, d, J = 
4.0 Hz), 4.12 (1H, d, J = 12.0 Hz), 4.23 (1H, d, J = 12.0 Hz), 4.34 (1H, d, J = 12.0 Hz), 4.54 
(1H, d, J = 12.0 Hz), 4.81 (1H, dd, J = 4.0 and J = 5.2 Hz) and 5.83 (1H, d, J = 4.0 Hz); 
13
C 
NMR (CDCl3, 100.6 MHz):  20.8, 20.8, 25.9, 26.2, 63.2, 64.4, 64.9, 79.9, 84.1, 104.3, 114.2, 
170.3 and 170.4; HR-ESI-TOF-MS: m/z 352.1106 ([M+Na]
+
), calcd. for [C13H19N3O7+Na]
+
 
352.1115. 
4-C-Acetoxymethyl-3-azido-3-deoxy-1,2-O-isopropylidene-α-D-ribofuranose (9). To a 
solution of compound 8 (3.5 g, 10.63 mmol) in THF (70 mL), n-butanol (1 mL, 10.9 mmol) 
were added followed by the addition of Novozyme
®
-435 (3.5 g, 35 % w/w of the compound 
8). The reaction mixture was stirred at 50 °C in an incubator shaker and the progress of the 
reaction was monitored periodically by TLC. On completion after 24 h, the reaction was 
quenched by filtering off the enzyme, the solvent was removed under reduced pressure and 
the residue thus obtained was purified by column chromatography using ethyl acetate in 
petroleum ether as gradient solvent system to afford the monodeacetylated compound 9 as a 
white solid (2.9 g, 95 % yield). Rf = 0.3 (40 % ethyl acetate in petroleum ether); M. Pt.: 72-74 
o
C; [α]D
26
 = + 57.48 (c = 0.1, MeOH); IR (thin film) max: 3351, 2924, 2114, 1738, 1458, 
1384, 1240, 1119, 1045 and 873 cm
-1
; 
1
H NMR (DMSO-d6, 400 MHz):  1.26 (3H, s), 1.47 
(3H, s), 2.02 (3H, s), 3.37-3.45 (2H, m), 4.10 (1H, d, J = 11.6 Hz), 4.34 (1H, d, J = 12.0 Hz), 
4.36 (1H, d, J = 5.2 Hz), 4.86 (1H, dd, J = 3.6 and J = 4.8 Hz), 5.16 (1H, brs) and 5.76 (1H, d, 
J = 3.6 Hz); 
13
C NMR (DMSO-d6, 100.6 MHz):  20.6, 25.8, 26.1, 62.2, 62.5, 63.2, 79.7, 
85.4, 104.0, 112.5 and 170.2; HR-ESI-TOF-MS: m/z 310.1015 ([M+Na]
+
), calcd. for 
[C11H17N3O6+Na]
+
 310.1010. 
4-C-(Acetoxymethyl)-3-azido-3-deoxy-5-O-(p-toluenesulphonyl)-1,2-O-isopropylidene-α-
D-ribofuranose (10).  To a stirred solution of compound 9 (3.5 g, 12.18 mmol) in pyridine 
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(15 mL), p-toluenesulfonyl chloride (4.1 g, 21.51 mmol) was added in three portions at 0 
o
C.  
The progress of the reaction was monitored by TLC and on completion after 4 h, the reaction 
mixture was neutralized by 10 % ice-cold hydrochloric acid solution (100 mL) and extracted 
with chloroform (3 x 100 mL). The combined organic extract was washed with saturated 
aqueous NaHCO3 (2 x 100 mL), dried over anhydrous Na2SO4, and the solvent was removed 
under reduced pressure. The residue thus obtained was purified by silica gel column 
chromatography using ethyl acetate in petroleum ether as gradient solvent system to afford 
the tosylated compound 10 as white solid (4.89 g; 91 % yield). Rf  = 0.6 (40 % ethyl acetate in 
petroleum ether); M. Pt.: 116-118 
o
C; [α]D
27
 = + 21.32 (c 0.1, MeOH); IR (thin film) max: 
2115, 1743, 1598, 1458, 1368, 1234, 1177, 1033, 817 and 667 cm
-1
; 
1
H NMR (CDCl3, 400 
MHz):  1.33 (3H, s), 1.60 (3H, s), 2.02 (3H, s), 2.47 (3H, s), 4.05-4.21 (4H, m), 4.47 (1H, d, 
J = 8.4 Hz), 4.78 (1H, t, J = 8.4 Hz), 5.74 (1H, d, J = 2.8 Hz), 7.38 (2H, d, J = 7.6 Hz) and 
7.80 (2H, d, J = 8.4 Hz); 
13
C NMR (CDCl3, 100.6 MHz):  20.6, 21.7, 25.9, 26.2, 62.8, 63.4, 
69.3, 79.9, 83.8, 104.4, 114.3, 128.0, 130.0, 132.2, 145.4 and 170.1; HR-ESI-TOF-MS: m/z 
464.1089 ([M+Na]
+
), calcd. for [C18H23N3O8S+Na]
+
 464.1098. 
 4-C-(Acetoxymethyl)-1,2-di-O-acetyl-3-azido-3-deoxy-5-O-(p-toluenesulphonyl)-α,β-D-
ribofuranose (11a-11b). Acetic anhydride (10.68 mL, 112.98 mmol) and concentrated 
sulphuric acid (0.058 mL, 1.09 mmol) was added to a stirred solution of compound 10 (5.0g, 
11.33 mmol) in acetic acid (64.84 mL, 1133.76 mmol) at 0 
o
C and mixture was stirred for 5 h. 
The reaction was quenched by addition of water (100 mL) and extracted with chloroform (3 x 
100 mL). The combined organic layer was washed with bicarbonate solution (2 x 100 mL), 
with cold water (2 x 100 mL) and then dried over sodium sulphate. The excess of solvent was 
removed under reduced pressure, the residue thus obtained was purified on silica gel column 
chromatography using ethyl acetate in petroleum ether as gradient solvent system to afford an 
anomeric mixture (α:β = 1:9, based on comparison of integration of anomeric proton) of  11a-
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11b as colourless oil (5.17 g, 94 %). Rf = 0.6 (40 % ethyl acetate in petroleum ether). IR (thin 
film) max: 2121, 1748, 1598, 1438, 1371, 1229, 1178, 1095, 1020, 993, 816 and 667 cm
-1
; 
Copy of 
1
H NMR (CDCl3, 400 MHz) and 
13
C NMR (CDCl3, 100.6 MHz) spectra are given in 
supporting information; HR-ESI-TOF-MS: m/z 508.0994 ([M+Na]
+
), calcd. for 
[C19H23N3O10S+Na]
+
 508.0996. 
General procedure for the synthesis of 4′-C-(acetoxymethyl)-2′-O-acetyl-3′-azido-3′-
deoxy-5′-O-(p-toluenesulfonyl)-ribonucleosides 12a-d. To the stirred solution of compound 
11a-11b (1.0 g, 2.0 mmol) and thymine (0.38 g, 3.0 mmol) / uracil (0.34 g, 3.0 mmol) or 
cytosine (0.34 g, 3.0 mmol) in anhydrous acetonitrile (20 mL), N,O-
bis(trimethylsilyl)acetamide (1.97 mL, 8.06 mmol) was added dropwise. 1,2-Dichloroethane 
was used as solvent for coupling of 6-N-benzoyladenine (0.73 g, 3.0 mmol) instead of 
acetonitrile. The reaction mixture was stirred at reflux for 1 h, and then cooled to 0 °C. In the 
cooled reaction mixture trimethylsilyltrifluoromethane sulfonate (0.61 mL, 3.37 mmol) was 
added dropwise under stirring and the reaction was heated at 70-80 °C for 4-6 h. The reaction 
was quenched with a cold saturated aqueous solution of sodium hydrogen carbonate (50 mL) 
and extraction was performed with chloroform (3 x 100 mL). The combined organic phase 
was washed with saturated aqueous solutions of NaHCO3 (2 x 100 mL) and brine (2 x 50 mL) 
and was dried over anhydrous Na2SO4. The excess of solvent was removed under reduced 
pressure and the residue thus obtained was purified by silica gel column chromatography 
using methanol in chloroform as gradient solvent system to afford nucleosides 12a-d in 81-
85 % yields.  
4'-C-(Acetoxymethyl)-2'-O-acetyl-3'-azido-3'-deoxy-5'-O-(p-toluenesulphonyl)thymidine 
(12a). It was obtained as off white solid (0.89 g, 81 %). Rf  = 0.6 (5 % methanol in 
chloroform); M. Pt.: 126-128 
o
C; [α]D
28
 = + 25.28 (c 0.1, MeOH); IR (thin film) max: 3199, 
2927, 2120, 1696, 1370, 1228, 1049, 998, 815, 732 and 667 cm
-1
; 
1
H NMR (CDCl3, 400 
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MHz):  1.92 (3H, s), 2.06 (3H, s), 2.18 (3H, s), 2.47 (3H, s), 4.07 (1H, d, J = 12.0 Hz), 4.23 
(2H, q, J = 8.4 Hz), 4.38 (1H, d, J = 12.4 Hz), 4.60 (1H, d, J = 6.4 Hz), 5.50 (1H, t, J = 5.6 
Hz), 5.87 (1H, d, J = 5.6 Hz), 7.17 (1H, s), 7.40 (2H, d, J = 8.4 Hz), 7.84 (2H, d, J = 8.4 Hz) 
and 8.90 (1H, brs); 
13
C NMR (CDCl3, 100.6 MHz):  12.3, 20.4, 20.7, 21.7, 62.4, 62.5, 69.2, 
74.2, 83.5, 88.7, 112.1, 128.0, 130.2, 131.9, 136.3, 145.8, 150.0, 163.4, 169.9 and 170.2; HR-
ESI-TOF-MS: m/z 574.1212 ([M+Na]
+
), calcd. for [C22H25N5O10S+Na]
+
 574.1214. 
 4'-C-(Acetoxymethyl)-2'-O-acetyl-3'-azido-3'-deoxy-5'-O-(p-toluenesulphonyl)uridine 
(12b). It was obtained as white solid (0.89 g, 83 %). Rf  = 0.6 (5 % methanol in chloroform); 
[α]D
28
 = + 34.60 (c 0.1, MeOH); IR (thin film) max: 3221, 2925, 2121, 1747, 1696, 1373, 
1229, 1178, 1049, 997, 913, 814, 733 and 667 cm
-1
; 
1
H NMR (DMSO-d6, 400 MHz):  1.94 
(3H, s), 2.09 (3H, s), 2.40 (3H, s), 4.04 (1H, d, J = 12.0 Hz), 4.15 (1H, d, J = 12.0 Hz), 4.28 
(2H, s), 4.81 (1H, d, J = 6.8 Hz), 5.56-5.65 (2H, m), 5.85 (1H, d, J = 5.2 Hz), 7.47 (2H, d, J = 
8.4 Hz), 7.57 (1H, d, J = 8.4 Hz), 7.80 (2H, d, J = 8.0 Hz) and 11.46 (1H, brs); 
13
C NMR 
(CDCl3, 100.6 MHz):  20.4, 20.6, 21.7, 62.2, 62.5, 68.9, 74.3, 83.7, 89.5, 103.2, 128.0, 
130.1, 131.9, 140.9, 145.8, 149.9, 162.8, 169.9 and 170.2; HR-ESI-TOF-MS: m/z 560.1059 
([M+Na]
+
), calcd. for [C21H23N5O10S+Na]
+
 560.1058. 
4'-C-(Acetoxymethyl)-2'-O-acetyl-3'-azido-3'-deoxy-5'-O-(p-toluenesulphonyl)-6-N-
benzoyladenosine (12c). It was obtained as yellow solid (1.09 g, 82 %). Rf  = 0.5 (5 % 
methanol in chloroform); M. Pt.: 75-77 
o
C; [α]D
29
 = + 29.81 (c 0.1, MeOH); IR (thin film) 
max: 3369, 2918, 2849, 2116, 1742, 1597, 1458, 1364, 1222, 1176, 1047, 815, 710 and 664 
cm
-1
; 
1
H NMR (CDCl3, 400 MHz):  2.04 (3H, s), 2.17 (3H, s), 2.47 (3H, s), 4.15 (1H, d, J = 
12.0 Hz), 4.31 (1H, d, J = 10.4 Hz), 4.39 (1H, d, J = 10.4 Hz),  4.54 (1H, d, J = 12.4 Hz), 
5.01 (1H, d, J = 6.0 Hz), 6.12-6.16 (2H, m), 7.36 (2H, d, J = 7.6 Hz), 7.53-7.63 (3H, m), 7.79 
(2H, d, J = 8.0 Hz), 8.03 (2H, d, J = 7.6 Hz), 8.07 (1H, s), 8.69 (1H, s) and
 
9.06 (1H, brs);
 13
C 
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NMR (CDCl3, 100.6 MHz):  20.3, 20.7, 21.7, 62.2, 62.8, 68.1, 74.3, 84.2, 87.0, 123.7 127.9, 
128.0, 128.9, 130.0, 132.0, 132.9, 133.3, 142.2, 145.6, 149.9, 151.2, 152.8, 164.5, 169.6 and 
170.2; HR-ESI-TOF-MS: m/z 665.1748 ([M+H]
+
), calcd. for [C29H28N8O9S+H]
+
 665.1773. 
4'-C-(Acetoxymethyl)-2'-O-acetyl-3'-azido-3'-deoxy-5'-O-(p-toluenesulphonyl)cytidine 
(12d). It was obtained as white solid (0.91 g, 85 %). Rf  = 0.3 (10 % methanol in chloroform); 
M. Pt.: 98-100 
o
C; [α]D
29
 = + 43.25 (c 0.1, MeOH); IR (thin film) max: 3345, 2962, 2121, 
1746, 1654, 1492, 1371, 1231, 1177, 1048, 995, 913, 789, 733 and 668 cm
-1
; 
1
H NMR 
(CDCl3, 400 MHz):  2.01 (3H, s), 2.15 (3H, s), 2.45 (3H, s), 4.02 (1H, d, J = 12.0 Hz), 4.25 
(2H, dd, J = 8.0 and J = 12.0 Hz), 4.41 (1H, d, J = 12.4 Hz), 4.78 (1H, d, J = 6.4 Hz), 5.56 
(1H, d, J = 3.6 Hz), 5.71 (1H, dd, J = 2.8 and 7.0 Hz ), 5.89 (1H, d, J = 7.2 Hz), 6.36 (1H, 
brs), 7.26 (1H, d, J = 6.0 Hz), 7.37 (2H, d, J = 8.0 Hz),  7.81 (2H, d, J = 8.0 Hz) and 8.10 (1H, 
brs); 
13
C NMR (CDCl3, 100.6 MHz):  22.6, 22.7, 23.7, 64.1, 65.1, 70.9, 77.0, 85.8, 95.2, 
97.8, 130.0, 132.1, 134.0, 145.3, 147.6, 157.3, 168.3, 171.9 and 172.3; HR-ESI-TOF-MS: 
m/z 537.1381 ([M+H]
+
), calcd. for [C21H24N6O9S+H]
+
 537.1398.  
General procedure for the synthesis of 3′-azido-3′-deoxy-C-4'-spiro-
oxetanoribonucleosides 13a-d. To a stirred solution of tosylated nucleosides 12a (0.5g, 0.91 
mmol), 12b (0.5g, 0.93 mmol), 12c (0.5g, 0.75 mmol) and 12d (0.5g, 0.93 mmol) (+NH4OH, 
2 mL for 12c) in dioxane : water (1:1, 4 mL) was added 2M, NaOH (4 mL) solution and the 
reaction mixture was stirred at RT for 24 h. On completion (analytical TLC), the reaction 
mixture was neutralized with acetic acid, the solvent was removed under reduced pressure. 
The residue thus obtained was purified by silica gel column chromatography using methanol 
in chloroform as gradient solvent system to afford 3'-azido-3'-deoxy-C-4'-spiro-
oxetanoribonucleosides 13a-d in 80-93 % yields.  
3'-Azido-3′-deoxy-C-4'-spiro-oxetanoribothymidine (13a). It was obtained as white solid 
(0.244 g, 91 %). Rf  = 0.3 (10 % methanol in chloroform); M. Pt.: 195-199 
o
C; [α]D
29
 = + 
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81.36 (c 0.1, MeOH); IR (thin film) max: 3385, 2923, 2113, 1688, 1219, 1054 and 772 cm
-1
; 
1
H NMR (DMSO-d6, 400 MHz):  1.77 (3H, s), 4.44 (1H, d, J = 7.6 Hz), 4.52 (1H, d, J = 8.0 
Hz), 4.60 (1H, d, J = 7.6 Hz), 4.69 (2H, d, J = 8.0 Hz), 4.81 (1H, dd, J = 4.0 Hz and J = 5.2 
Hz  ), 5.63 (1H, d, J = 6.4 Hz), 6.21 (1H, s), 7.47 (1H, s) and 11.39 (1H, brs); 
13
C NMR 
(DMSO-d6, 100.6 MHz):  12.0, 66.1, 71.9, 77.6, 81.1, 83.1, 89.7, 109.9, 137.8, 150.7 and 
163.8; HR-ESI-TOF-MS: m/z 296.0987 ([M+H]
+
), calcd. for [C11H13N5O5+H]
+
 296.0989. 
3'-Azido-3′-deoxy-C-4'-spiro-oxetanoribouridine (13b). It was obtained as white solid 
(0.243 g; 93 %). Rf  = 0.3 (10 % methanol in chloroform); M. Pt.: 90-92 
o
C; [α]D
30
 = +79.22 (c 
0.1, MeOH); IR (thin film) max: 3431, 2926, 2854, 2116, 1654, 1440, 1095 and 555 cm
-1
; 
1
H 
NMR (DMSO-d6, 400 MHz):  4.44 (1H, d, J = 7.2 Hz), 4.51 (1H, d, J = 8.0 Hz), 4.59 (1H, 
d, J = 7.2 Hz), 4.67 (1H, d, J = 7.6 Hz), 4.69 (1H, d, J = 4.4 Hz),  4.81 (1H, s), 5.62 – 5.65 
(2H, m), 6.22 (1H, brs), 7.62 (1H, d, J = 8.0 Hz) and 11.39 (1H, brs); 
13
C NMR (DMSO-d6, 
100.6 MHz):  65.9, 71.9, 77.5, 80.9, 83.2, 90.3, 102.1, 142.5, 150.6 and 163.1; HR-ESI-
TOF-MS: m/z 282.0844 ([M+H]
+
), calcd. for [C10H11N5O5+H]
+
 282.0833. 
3'-Azido-3′-deoxy-C-4'-spiro-oxetanoriboadenosine (13c). It was obtained as yellow solid 
(0.205 g; 90 % yield). Rf = 0.3 (10 % methanol in chloroform); M. Pt.: 150-152 
o
C; [α]D
30
 = + 
44.28 (c 0.1, MeOH); IR (thin film) max: 3392, 2922, 2117, 1640, 1261, 1125, 1097, 1012, 
772 and 687 cm
-1
; 
1
H NMR (DMSO-d6, 400 MHz):  3.34 (1H, brs), 4.47 (1H, d, J = 8.4 Hz), 
4.60 (1H, d, J = 8.0 Hz), 4.71 (2H, d, J = 8.0 Hz), 4.88 (1H, d, J = 4.4 Hz), 5.42 (1H, dd, J = 
4.4 and J = 7.6 Hz), 5.90 (1H, d, J = 7.2 Hz), 7.32 (2H, brs), 8.11 (1H, s) and 8.32 (1H, s); 
13
C NMR (DMSO-d6, 100.6 MHz):  66.5, 72.5, 77.2, 81.2, 83.3, 87.6, 119.7, 140.7, 149.3, 
152.6 and 156.2; HR-ESI-TOF-MS: m/z 305.1105 ([M+H]
+
), calcd. for [C11H12N8O3+H]
+
 
305.1105. 
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3'-Azido-3′-deoxy-C-4'-spiro-oxetanoribocytidine (13d). It was obtained as white solid 
(0.208 g; 80 % yield). Rf  = 0.3 (10 % methanol in chloroform); M. Pt.: 190-194 
o
C; [α]D
30
 = 
+ 48.53 (c 0.1, MeOH); IR (thin film) max: 3351, 2921, 2115, 1648, 1497, 1219, 1125, 1034, 
1012, 772 and 687 cm
-1
; 
1
H NMR (DMSO-d6, 400 MHz):  4.45 (1H, d, J = 7.6 Hz), 4.57 
(2H, dd, J = 4.0 and J = 5.2 Hz), 4.63 (1H, d, J = 4.2 Hz), 4.67 (1H, d, J = 7.2 Hz), 4.89 (1H, 
dd, J = 4.0 Hz and J = 5.2 Hz) 5.56 (1H, d, J = 5.6 Hz), 5.72 (1H, d, J = 7.2 Hz), 6.11 (1H, d, 
J = 5.2 Hz), 7.24 (2H, d, 12.0 Hz) and 7.54 (1H, d, J = 7.2 Hz); 
13
C NMR (DMSO-d6, 100.6 
MHz):  66.1, 72.1, 77.5, 81.1, 83.2, 92.2, 94.3, 143.6, 155.1 and 165.7; HR-ESI-TOF-MS: 
m/z 281.1001 ([M+H]
+
), calcd. for [C10H12N6O4+H]
+
 281.0993. 
3'-Amino-3′-deoxy-C-4'-spiro-oxetanoribothymidine (14). The reduction of azido group of 
spironucleoside 13a (0.5g, 1.69 mmol) was achieved by reaction with 10% Pd-C (0.05g) in 
ethyl acetate (15 mL) under hydrogen atmosphere at 28 
o
C. The progress of the reaction was 
monitored by analytical TLC. On completion after 2 h, the reaction was quenched by filtering 
off the Pd-C, the solvent was removed under reduced pressure and the residue thus obtained 
was purified by silica gel column chromatography using methanol in chloroform as eluent to 
afford the spironucleoside 14 as white solid (0.450 g; 99 % yield). Rf = 0.2 (10 % methanol in 
chloroform); M. Pt.: 146-148 
o
C; [α]D
30
 = + 52.09 (c 0.1, MeOH); IR (thin film) max: 3413, 
1700, 1458, 1268, 1054 and 970 cm
-1
; 
1
H NMR (DMSO-d6, 400 MHz):  1.77 (3H, s), 3.39 
(2H, d, J = 4.0 Hz), 4.09 (1H, s), 4.35 (1H, d, J = 6.8 Hz), 4.62 (2H, s), 4.77 (2H, d, J = 6.8 
Hz), 5.68 (1H, d, J = 2.4 Hz), 5.69 (1H, brs), 7.31 (1H, s) and 11.34 (1H, brs); 
13
C NMR 
(DMSO-d6, 100.6 MHz):  12.1, 55.9, 72.9, 77.7, 79.2, 79.8, 89.9, 109.6, 136.6, 150.6 and 
163.9; HR-ESI-TOF-MS: m/z 270.1083 ([M+H]
+
), calcd. for [C11H15N3O5+H]
+
 270.1084. 
General procedure for the synthesis of 4′-C-(Acetoxymethyl)-2′-O-acetyl-3′-O-benzyl-5′-
O-(p-toluenesulfonyl)-ribonucleosides 17a & 17b. To the stirred solution of tri-O-acetylated 
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sugar derivative 16a-16b (0.50 g, 0.91 mmol) and 6-N-benzoyladenine (1.36 mmol) in 
anhydrous dichloroethane (20 mL), N,O-bis (trimethylsilyl)acetamide (0.91 mL, 3.72 mmol) 
was added dropwise. Under the condition of coupling of 6-N-benzoyladenine, acetonitrile was 
used as solvent instead of dichloroethane for coupling of cytosine (1.36 mmol). The reaction 
mixture was stirred at reflux for 1 h, and then cooled to 0 
o
C. In the cooled reaction mixture 
trimethylsilyltrifluoromethane sulfonate (0.28 mL, 1.55 mmol) was added dropwise under 
stirring and the solution was heated at 70-80 
o
C for 6-10 h. The reaction was quenched with 
cold saturated aq. solution of sodium bicarbonate (100 mL) and extraction was performed with 
dichloromethane (3 x 100 mL). The combined organic phase was washed with saturated aq. 
sodium bicarbonate solution (2 x 100 mL), brine solution (2 x 100 mL), and was dried over 
anhydrous sodium sulphate. The excess of solvent was removed under reduced pressure and the 
residue thus obtained was purified by silica gel column chromatography using methanol in 
chloroform as eluent to afford nucleosides 17a & 17b in 74 & 81 % yield. 
4′-C-(Acetoxymethyl)-2′-O-acetyl-3′-O-benzyl-5′-O-(p-toluenesulfonyl)-6-N-
benzoyladenosine (17a). It was obtained as white solid (0.49 g, 74 % yield). Rf  = 0.4 (5 % 
methanol in chloroform); M. Pt.: 96-98 
o
C; [α]D
32
 = + 13.3 (c 0.05, MeOH); IR (thin film) max: 
3327, 3066, 3031, 2927, 1747, 1706, 1610, 1584, 1483, 1456, 1367, 1238, 1177, 1097, 1050 
and 756 cm
-1
; 
1
H NMR (CDCl3, 400 MHz):  2.00 (3H, s), 2.09 (3H, s), 2.43 (3H, s), 4.14 (1H, 
d, J = 12.4 Hz), 4.20 (1H, d, J = 10.0 Hz), 4.29 (1H, d, J = 10.8 Hz), 4.59 (2H, dd, J = 11.2 and 
16.0 Hz), 4.65 (1H, d, J = 8.4 Hz), 4.93 (1H, d, J = 6.8 Hz), 5.96 (1H, dd, J = 3.6 and 6.0 Hz), 
6.13 (1H, d, J = 3.6 Hz), 7.26-7.37 (7H, m), 7.52-7.55 (2H, m), 7.60-7.64 (1H, m), 7.68 (2H, d, 
J = 8.0 Hz), 8.03-8.08 (3H, m), 8.69 (1H, s), 9.11 (1H, brs);
 13
C NMR (CDCl3, 100.6 MHz):  
20.6, 20.7, 21.6, 62.1, 68.1, 73.8, 74.6, 77.7, 84.5, 87.5, 123.5, 127.8, 127.9, 128.1, 128.3, 
128.5, 128.8, 129.8, 132.2, 132.8, 133.4, 136.6, 142.2, 145.3, 149.8, 152.6, 164.7, 169.6 and 
170.4; HR-ESI-TOF-MS: m/z 730.2175 ([M+H]
+
), calcd. for [C36H35N5O10S+H]
+
 730.2177. 
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4′-C-(Acetoxymethyl)-2′-O-acetyl-3′-O-benzyl-5′-O-(p-toluenesulfonyl)cytidine (17b). It was 
obtained as white solid (0.443 g, 81 % yield). Rf  = 0.3 (10 % methanol in chloroform); M. Pt.: 
205-206 
o
C; [α]D
32
 = + 26.8 (c 0.05, MeOH); IR (thin film) max: 3300, 3092, 1743, 1647, 1492, 
1369, 1293, 1234, 1190, 1176, 1111, 1045, 989, 814, 790, 755 and 699 cm
-1
; 
1
H NMR (CDCl3, 
400 MHz):  1.95 (3H, s), 2.04 (3H, s), 2.41 (3H, s), 4.03 (1H, d, J = 12.4 Hz), 4.12 (1H, d, J = 
11.2 Hz), 4.25 (1H, d, J = 10.8 Hz), 4.37 (1H, d, J = 11.2 Hz), 4.48-4.53 (3H, m), 5.53 (1H, dd, 
J = 2.8 and 6.4 Hz), 5.69 (1H, d, J = 2.4 Hz), 6.00 (1H, d, J = 8.0 Hz), 7.18-7.20 (2H, m), 7.27-
7.38 (7H, m), 7.74 (2H, d, J = 8.0 Hz), 8.18 (1H, brs);
 13
C NMR (CDCl3, 100.6 MHz): δ 20.7, 
20.8, 21.7, 62.3, 68.7, 74.2, 74.4, 77.8, 84.3, 92.3, 95.7, 127.9, 128.0, 128.4, 130.1, 132.2, 
137.0, 142.9, 145.5, 154.1, 164.6, 169.8 and 170.4; HR-ESI-TOF-MS: m/z 624.1632 
([M+Na]
+
), calcd. for [C28H31N3O10S+Na]
+
 624.1622. 
General procedure for the synthesis of 3′-O-benzyl-C-4'-spiro-oxetanoribonucleosides 18a & 
18b. To a stirred solution of compound 17a & 17b (0.67 mmol) in dioxane:water (2 mL, 1:1), 
2M NaOH (1.5 mL) (+NH4OH, 1ml for 17a only) was added and reaction mixture was stirred 
at 28 
o
C for 30-45 h. The reaction mixture was neutralized with acetic acid and co-evaporated 
with toluene under reduced pressure. The residue thus obtained was purified by silica gel 
column chromatography using methanol in chloroform as gradient solvent system to give 18a 
& 18b in 68 & 71 % yield. 
3′-O-Benzyl-C-4′-spiro-oxetanoriboadenosine (18a). It was obtained as white solid (168 mg, 
68 % yield). Rf = 0.4 (25 % MeOH in CHCl3); M. Pt.: 96-98 
o
C; [α]D
32
 = + 46.87 (c 0.1, 
MeOH); IR (KBr) max: 3399, 2927, 1628, 1410, 1238, 1094, 966, 862 and 678 cm
-1
; 
1
H NMR 
(DMSO-d6, 400 MHz): δ  4.46-4.48 (2H, m), 4.65 (2H, dd, J = 8.0 and 20.8 Hz),  4.73-4.79 
(2H, m),  4.98 (1H, d, J = 11.6 Hz),  5.04-5.07 (1H, m), 5.83 (1H, brs), 5.93 (1H, d, J = 6.0 Hz), 
7.29-7.33 (3H, m),  7.36-7.40 (2H, m),  7.43-7.45 (2H, brs),  8.10 (1H, s), 8.29 (1H, s); 
13
C 
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NMR (DMSO-d6, 100.6 MHz): δ 72.4, 72.8, 77.6, 80.5, 80.6, 84.0, 88.0, 119.5, 127.7, 127.9, 
128.3, 138.5, 140.4, 149.2, 152.6 and 156.1; HR-ESI-TOF-MS m/z 370.1496 ([M+H]
+
), calcd. 
for [C18H19N5O4+H]
+
 370.1510. 
3′-O-Benzyl-C-4′-spiro-oxetanoribocytidine (18b). It was obtained as white solid (164 mg, 
71 % yield). Rf  = 0.4 (25 % methanol in chloroform); M. Pt.: 130-132 
o
C; [α]D
32
 = + 80.72 (c 
0.05, MeOH); IR (KBr) max: 3422, 2928, 1641, 1484, 1282, 1123, 1103, 1054 and 787 cm
-1
; 
1
H NMR (DMSO-d6, 400 MHz): δ 4.09 (1H, d, J = 4.0 Hz), 4.41-4.43 (2H, m), 4.58-4.66 (3H, 
m), 4.77 (1H, d, J = 6.4 Hz), 4.87 (1H, d, J = 7.6 Hz), 5.61 (1H, brs), 5.65 (1H, d, J = 4.4 Hz), 
5.70 (1H, dd, J = 1.6 and 7.2 Hz), 7.15 (1H, brs), 7.21 (1H, brs), 7.30 (1H, d, J = 7.2 Hz), 7.34-
7.45 (5H, m); 
13
C NMR (DMSO-d6, 100.6 MHz):  δ 71.9, 72.3, 78.0, 79.7, 80.0, 83.8, 91.8, 
94.2, 127.6, 127.7, 128.3, 138.5, 142.2, 155.1 and 165.7; HR-ESI-TOF-MS: m/z 346.1402 
([M+H]
+
), calcd. for [C17H19N3O5+H]
+
 346.1397. 
C-4'-spiro-oxetanoriboadenosine (19). To a stirred solution of nucleoside 18a (0.10 g, 0.27 
mmol) in anhydrous EtOH (6 mL) was added 20 % Pd(OH)2-C (0.03 g) and ammonium 
formate (0.09 g, 1.43 mmol). The reaction mixture was refluxed for 4 h whereupon it was 
cooled to rt. The catalyst was carefully filtered off, washed with excess MeOH and the 
combined filtrate was concentrated. The crude product thus obtained was purified by silica 
gel column chromatography using methanol in chloroform as gradient solvent system to 
afford spironucleoside 19 as sticky solid (0.055 g, 73 % yield). Rf  = 0.2 (25 % MeOH in 
CHCl3); [α]D
29
 = - 5.13 (c 0.1, MeOH); IR (KBr) max: 3166, 2886, 1713, 1628, 1418, 1234, 
1044, 969 and 699 cm
-1
; 
1
H NMR (DMSO-d6, 400 MHz): δ  4.39 (1H, d, J = 4.4 Hz),  4.45 
(1H, d, J = 7.2 Hz), 4.61 (2H, dd, J = 7.2 and 18.8 Hz), 4.79 (1H, d, J = 7.2 Hz), 4.90 (1H, 
m), 5.58 (1H, brs), 5.71 (1H, brs), 5.86 (1H, d, J = 6.8 Hz), 7.27 (2H, brs),  8.11 (1H, s), 8.29 
(1H, s); 
13
C NMR (DMSO-d6, 100.6 MHz): δ 72.3, 73.5, 77.2, 80.8, 84.6, 87.6, 119.5, 140.4, 
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149.3, 152.5 and 156.1; HR-ESI-TOF-MS: m/z 280.1052 ([M+H]
+
), calcd. for 
[C11H13N5O4+H]
+
 280.1040. 
X-Ray diffraction study of 4-C-(acetoxymethyl)-3-azido-3-deoxy-5-O-(p-
toluenesulphonyl)-1,2-O-isopropylidene-α-D-ribofuranose (10) and 3′-O-benzyl-C-4′-
spiro-oxetanoribouridine (20). 
Single crystal suitable for X-ray diffraction was grown by dissolving tosylated sugar 
derivative 10 and 3′-O-benzyl-C-4′-spiro-oxetanoribouridine (20) in toluene and chloroform 
respectively and allowing slow evaporation of the solution at room temperature. The X-ray 
diffraction data was collected on an Oxford Diffraction X’Calibur CCD diffractometer with 
graphite monochromated Cu Kα radiation (λ = 1.54184 Å) at temperature 298 K. The 
structure was solved by direct methods using SHELXS-97 and refined by full-matrix least-
squqres method on F
2
 (SHELXL-97).
16
 All calculations were carried out using the WinGX 
package of the crystallographic programs.
17
 For the molecular graphics, the program 
DIAMOND-2
18
 and Mercury
19
 was used. Molecular structure have been drawn using ORTEP 
as software as given in Figures 2 and 3. The selected bond lengths, bond angles, etc. are 
given in Tables 1 and 2.  
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Figure 1. Structures of natural and synthetic spirocyclic nucleosides 
Figure 2. ORTEP diagram of compound 10 drawn in 20% thermal probability ellipsoids 
showing atomic numbering scheme.      
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Figure 3a: ORTEP diagram of compound 20 drawn in 20 % thermal probability ellipsoids 
showing atomic numbering scheme. 
 
Figure 3b: Preferential N-type sugar ring puckering in compound 20. 
 
Table 1. Single crystal X-ray diffraction data of tosylated sugar derivative 10 
Compound 10 
Empirical formula C18 H23 N3 O8 S  
Formula weight 441.45 
Temperature 298(2) K 
Wavelength 0.71073 Å 
Crystal system Monoclinic 
Space group P 21 
Unit cell dimensions 
a = 6.6548(4) Å 
α = 90° 
b = 16.0022(7) Å 
β = 99.431(6)° 
c = 10.3544(6) Å 
γ = 90° 
Volume 1087.75(10) Å
3
 
Z 2 
Density (calculated) 1.348 Mg/m
3
 
Absorption coefficient 0.197 mm
-1
 
F(000) 464 
Crystal size 0.22 x 0.16 x 0.12 mm
3
 
Theta range for data collection 3.23 to 25.00°. 
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Index ranges 
-7<=h<=7,  
-19<=k<=19,  
-12<=l<=12 
Reflections collected 8191 
Independent reflections 3731 [R(int) = 0.0189] 
Completeness to theta = 25.00 
o
 99.4 % 
Max. and min. transmission 0.9767 and 0.9579 
Refinement method 
Full-matrix least-
squares on F
2
 
Data / restraints / parameters 3731 / 1 / 275 
Goodness-of-fit on F2 1.045 
Final R indices [I>2sigma(I)] 
R1 = 0.0366, 
wR2 = 0.0834 
R indices (all data) 
R1 = 0.0415, 
wR2 = 0.0859 
Absolute structure parameter -0.01(7) 
Largest diff. peak and hole 0.173 and -0.169 e.Å
-3
 
CCDC 951084 
 
 
Table 2: Single crystal X-ray diffraction data of 3′-O-benzyl-C-4′-spiro-oxetanoribouridine 
(20). 
Compound 20 
Empirical formula  C17H18N2O6 
Formula weight  346.33 
Temperature  298(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
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Space group  P 21 
Unit cell dimensions 
a = 6.4248(18) Å, α = 90° 
b = 7.327(2) Å, β = 92.47(3)° 
c = 18.217(5) Å, γ = 90° 
Volume 856.7(4) Å
3 
Z 2 
Density (calculated) 1.405 mg / m
3
 
Absorption coefficient 0.111 mm
-1
 
F(000) 380.0 
Crystal size 0.13 x 0.12 x 0.10 mm
3
 
Theta range for data 
collection 
3.00 to 25.00°. 
Index ranges -7≤h≤7, -8≤k≤8, -20≤l≤21 
Reflections collected 5047 
Independent reflections 2971 [R(int) = 0.1457] 
Completeness to theta = 
25.00° 
99.7 %  
Absorption correction Semi-empirical from 
equivalents 
Max. and min. 
transmission 
0.9890 and 0.9858 
Refinement method Full-matrix least-squares on F
2 
Data / restraints / 
parameters 
2971 / 243 / 205 
Goodness-of-fit on F
2 1.541 
Final R indices [I>2σ(I)] R1 = 0.1735, wR2 = 0.4136 
R indices (all data) R1 = 0.2116, wR2 = 0.4475 
Absolute structure 
parameter 
4(6) 
Largest diff. peak and 
hole 
0.552 and -0.515 e.Å
-3 
CCDC 1032754 
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Scheme 1. Lipase-mediated deacetylation studies on diacetoxy sugar derivative 8    
Scheme 2. Synthesis of 3'-azido- / 3'-amino-C-4'-spiro-oxetanoribonucleosides 13a-d and 14 
Scheme 3. Synthesis of C-4'-spiro-oxetanoribonucleosides 18a & 18b and 19 
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